Article Text

Download PDFPDF
Carboplatin and chlorambucil combination chemotherapy as treatment for patients with ovarian cancer
  1. B. D. Evans*,**,
  2. P. Chapman,
  3. P. Dady,
  4. G. Forgeson*,
  5. D. Perez§,
  6. M. Mckeage,†† and
  7. P. Mitchell
  1. * Oncology Unit, Palmerston North Hospital, Palmerson North;
  2. Oncology Unit, Waikato Hospital, Hamilton;
  3. Oncology Unit, Wellington Hospital, Wellington;
  4. § Oncology Unit, Dunedin Hospital, Dunedin; and
  5. Oncology Unit, Auckland Hospital, Auckland, New Zealand
  6. ** Present address: Oncology Unit, Auckland Hospital, Auckland, New Zealand.
  7. †† Present address: Institute of Cancer Research, Downs Road, Sutton, Surrey, England.
  1. Address for correspondence: B. D. Evans, Oncology Unit, Auckland Hospital, Park Road, Auckland, New Zealand.


Fifty-six patients with ovarian cancer (three stage IC, nine stage II, 33 stage III and II stage IV) were treated with carboplatin 350 mg m−2 i.v. day 1 and chlorambucil orally 0.15 mg kgm−1 days 1–7 inclusive, repeated every 28 days for eight courses. The regimen was well tolerated and was virtually free of nephro- and neurotoxicity. Grade III or IV hematology toxicity occurred in 18 patients but only 31 or 330 courses administered were delayed. Of 40 assessable patients eight achieved a clinical/radiologic complete response and 17 a clinical/radiologic partial response. Actuarial survival at 50 months was 65% for stage II patients, 27% for stage III patients and no stage IV patients survived beyond 20 months. Forty-two per cent of patients with residual disease less 2 cm survived 50 months, compared with 44% of patients with moderate volume (2–5 cm) residual disease and 6% of patients with bulk residual disease. This is an active, well tolerated regimen. However, only patients with small volume residual disease have a significant chance of prolonged survival.

  • chemotherapy
  • ovarian cancer.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.